279 related articles for article (PubMed ID: 31300350)
1. Aryl hydrocarbon receptor nuclear translocator-like (ARNTL/BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor A.
Burgermeister E; Battaglin F; Eladly F; Wu W; Herweck F; Schulte N; Betge J; Härtel N; Kather JN; Weis CA; Gaiser T; Marx A; Weiss C; Hofheinz R; Miller IS; Loupakis F; Lenz HJ; Byrne AT; Ebert MP
EBioMedicine; 2019 Jul; 45():139-154. PubMed ID: 31300350
[TBL] [Abstract][Full Text] [Related]
2. FOXF1 promotes angiogenesis and accelerates bevacizumab resistance in colorectal cancer by transcriptionally activating VEGFA.
Wang S; Xiao Z; Hong Z; Jiao H; Zhu S; Zhao Y; Bi J; Qiu J; Zhang D; Yan J; Zhang L; Huang C; Li T; Liang L; Liao W; Ye Y; Ding Y
Cancer Lett; 2018 Dec; 439():78-90. PubMed ID: 30253191
[TBL] [Abstract][Full Text] [Related]
3. Tumour-infiltrating neutrophils counteract anti-VEGF therapy in metastatic colorectal cancer.
Schiffmann LM; Fritsch M; Gebauer F; Günther SD; Stair NR; Seeger JM; Thangarajah F; Dieplinger G; Bludau M; Alakus H; Göbel H; Quaas A; Zander T; Hilberg F; Bruns CJ; Kashkar H; Coutelle O
Br J Cancer; 2019 Jan; 120(1):69-78. PubMed ID: 30377339
[TBL] [Abstract][Full Text] [Related]
4. Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival.
Paiva TF; de Jesus VH; Marques RA; da Costa AA; de Macedo MP; Peresi PM; Damascena A; Rossi BM; Begnami MD; de Lima VC
BMC Cancer; 2015 Sep; 15():643. PubMed ID: 26394830
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of the circadian clock gene Bmal1 increases sensitivity to oxaliplatin in colorectal cancer.
Zeng ZL; Luo HY; Yang J; Wu WJ; Chen DL; Huang P; Xu RH
Clin Cancer Res; 2014 Feb; 20(4):1042-52. PubMed ID: 24277452
[TBL] [Abstract][Full Text] [Related]
6. Genetic Variants of
Gaibar M; Galán M; Romero-Lorca A; Antón B; Malón D; Moreno A; Fernández-Santander A; Novillo A
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33573134
[TBL] [Abstract][Full Text] [Related]
7. Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial.
Pineda E; Salud A; Vila-Navarro E; Safont MJ; Llorente B; Aparicio J; Vera R; Escudero P; Casado E; Bosch C; Bohn U; Pérez-Carrión R; Carmona A; Ayuso JR; Ripollés T; Bouzas R; Gironella M; García-Albéniz X; Feliu J; Maurel J
Tumour Biol; 2017 Jun; 39(6):1010428317705509. PubMed ID: 28621236
[TBL] [Abstract][Full Text] [Related]
8. Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model.
Iwai T; Sugimoto M; Harada S; Yorozu K; Kurasawa M; Yamamoto K
Oncol Rep; 2016 Aug; 36(2):626-32. PubMed ID: 27350037
[TBL] [Abstract][Full Text] [Related]
9. Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients.
Carbone C; Piro G; Simionato F; Ligorio F; Cremolini C; Loupakis F; Alì G; Rossini D; Merz V; Santoro R; Zecchetto C; Zanotto M; Di Nicolantonio F; Bardelli A; Fontanini G; Tortora G; Melisi D
Clin Cancer Res; 2017 Aug; 23(15):4312-4322. PubMed ID: 28298545
[No Abstract] [Full Text] [Related]
10. Upregulation of circadian gene 'hClock' contribution to metastasis of colorectal cancer.
Wang Y; Sun N; Lu C; Bei Y; Qian R; Hua L
Int J Oncol; 2017 Jun; 50(6):2191-2199. PubMed ID: 28498393
[TBL] [Abstract][Full Text] [Related]
11. Identification of a novel circadian clock modulator controlling BMAL1 expression through a ROR/REV-ERB-response element-dependent mechanism.
Lee J; Lee S; Chung S; Park N; Son GH; An H; Jang J; Chang DJ; Suh YG; Kim K
Biochem Biophys Res Commun; 2016 Jan; 469(3):580-6. PubMed ID: 26692477
[TBL] [Abstract][Full Text] [Related]
12. Cell-free DNA analysis reveals POLR1D-mediated resistance to bevacizumab in colorectal cancer.
Zhou Q; Perakis SO; Ulz P; Mohan S; Riedl JM; Talakic E; Lax S; Tötsch M; Hoefler G; Bauernhofer T; Pichler M; Gerger A; Geigl JB; Heitzer E; Speicher MR
Genome Med; 2020 Feb; 12(1):20. PubMed ID: 32087735
[TBL] [Abstract][Full Text] [Related]
13. Anti-angiogenic therapies for metastatic colorectal cancer.
Wagner AD; Arnold D; Grothey AA; Haerting J; Unverzagt S
Cochrane Database Syst Rev; 2009 Jul; (3):CD005392. PubMed ID: 19588372
[TBL] [Abstract][Full Text] [Related]
14. Changes in expression levels of ERCC1, DPYD, and VEGFA mRNA after first-line chemotherapy of metastatic colorectal cancer: results of a multicenter study.
Baba H; Baba Y; Uemoto S; Yoshida K; Saiura A; Watanabe M; Maehara Y; Oki E; Ikeda Y; Matsuda H; Yamamoto M; Shimada M; Taketomi A; Unno M; Sugihara K; Ogata Y; Eguchi S; Kitano S; Shirouzu K; Saiki Y; Takamori H; Mori M; Hirata T; Wakabayashi G; Kokudo N
Oncotarget; 2015 Oct; 6(32):34004-13. PubMed ID: 26372896
[TBL] [Abstract][Full Text] [Related]
15. Targeting tumor cell-derived CCL2 as a strategy to overcome Bevacizumab resistance in ETV5
Feng H; Liu K; Shen X; Liang J; Wang C; Qiu W; Cheng X; Zhao R
Cell Death Dis; 2020 Oct; 11(10):916. PubMed ID: 33099574
[TBL] [Abstract][Full Text] [Related]
16. Single-nucleotide polymorphisms in the vascular endothelial growth factor pathway and outcomes of patients treated with first-line cytotoxic chemotherapy combined with bevacizumab for advanced colorectal cancer.
Sohn BS; Park SJ; Kim JE; Kim KP; Hong YS; Suh C; Kim YS; Kim SY; Im SA; Kim SY; Kim JH; Ahn JB; Park YS; Kim TW
Oncology; 2014; 87(5):280-92. PubMed ID: 25139485
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms.
Wagner J; Kline CL; Zhou L; Khazak V; El-Deiry WS
J Exp Clin Cancer Res; 2018 Jan; 37(1):11. PubMed ID: 29357916
[TBL] [Abstract][Full Text] [Related]
18. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
[TBL] [Abstract][Full Text] [Related]
19.
Papachristos A; Kemos P; Katsila T; Panoilia E; Patrinos GP; Kalofonos H; Sivolapenko GB
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31752122
[TBL] [Abstract][Full Text] [Related]
20. MiR-590-5p inhibits colorectal cancer angiogenesis and metastasis by regulating nuclear factor 90/vascular endothelial growth factor A axis.
Zhou Q; Zhu Y; Wei X; Zhou J; Chang L; Sui H; Han Y; Piao D; Sha R; Bai Y
Cell Death Dis; 2016 Oct; 7(10):e2413. PubMed ID: 27735951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
